Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 14Recruiting 4Terminated 2No longer available 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 31Gastrointestinal 31Thoracic 3Head & Neck 2Gynecologic 2Endocrine 2CNS 2NET 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Brain Neoplasms 276Glioblastoma 250Glioma 156Astrocytoma 99Central Nervous System Neoplasms 70Gliosarcoma 69Oligodendroglioma 63Neuroblastoma 63Neoplasms 52Breast Neoplasms 44Melanoma 42Carcinoma, Non-Small-Cell Lung 38Neoplasm Metastasis 33Medulloblastoma 30Lymphoma 29Recurrence 28Lung Neoplasms 27Ependymoma 24Sarcoma 20Ovarian Neoplasms 19Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Meningioma 18Lymphoma, Non-Hodgkin 18Leukemia 18Meningeal Carcinomatosis 17Burkitt Lymphoma 17Multiple Myeloma 16Lymphoma, Large B-Cell, Diffuse 16Diffuse Intrinsic Pontine Glioma 15

Interventions

guadecitabine 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Stromal Tumors × CNS × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

NCT00585221 2017-02-10

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

University of Utah

Phase 2 Terminated
8 enrolled 4 charts
CNSGastrointestinalSarcoma

Brain Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡